CLAIMS

1. Use of

   (a) a therapeutically effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, and

   (b) a therapeutically effective amount of fesoterodine, or a pharmaceutically acceptable salt thereof,

   in the manufacture of a medicament for treating schizophrenia or Alzheimer's disease psychosis in a patient in need thereof.

2. The use of claim 1, wherein the patient is treated for schizophrenia.

3. The use of claim 1, wherein the patient is treated for Alzheimer's disease psychosis.

4. The use of any one of claims 1-3, wherein about 5 mg to about 800 mg of Compound 1, or a pharmaceutically acceptable salt thereof is to be administered to the patient.

5. The use of claim 4, wherein about 20 mg to about 80 mg of Compound 1, or a pharmaceutically acceptable salt thereof is to be administered to the patient.

6. The use of claim 4, wherein about 60 mg of Compound 1, or a pharmaceutically acceptable salt thereof is to be administered to the patient.

7. The use of any one of claims 1-6, wherein the administration provides a therapeutically effective steady-state plasma concentration of Compound 1.

8. The use of claim 7, wherein the therapeutically effective steady-state plasma concentration of Compound 1 is about 100 ng/mL to about 2500 ng/mL.

9. The use of claim 7, wherein the therapeutically effective steady-state plasma concentration of Compound 1 is about 600 ng/mL.

10. The use of any one of claims 1-9, wherein about 1 mg to about 50 mg of fesoterodine, or a pharmaceutically acceptable salt thereof is to be administered to the patient.

11. The use of claim 10, wherein about 8 mg of fesoterodine, or a pharmaceutically acceptable salt thereof is to be administered.

12. The use of claim 10, wherein about 24 mg of fesoterodine, or a pharmaceutically acceptable salt thereof is to be administered.

13. The use of any one of claims 1-12, wherein the administration provides a therapeutically effective steady-state plasma concentration of desfesoterodine (i.e., an amount sufficient to reduce peripheral side effects associated with administration of Compound 1).

14. The use of claim 13, wherein the therapeutically effective steady-state plasma concentration of desfesoterodine is about 5 ng/mL to about 30 ng/mL.

15. The use of any one of claims 1-14, wherein the Compound 1, or a pharmaceutically acceptable salt thereof is to be administered once per day.

16. The use of any one of claims 1-14, wherein the Compound 1, or a pharmaceutically acceptable salt thereof is to be administered twice per day.

17. The use of any one of claims 1-14, wherein the Compound 1, or a pharmaceutically acceptable salt thereof is to be administered three times per day.

18. The use of any one of claims 1-17, wherein the fesoterodine, or a pharmaceutically acceptable salt thereof is to be administered once per day.

19. The use of any one of claims 1-17, wherein the fesoterodine, or a pharmaceutically acceptable salt thereof is to be administered twice per day.

20. The use of any one of claims 1-17, wherein the fesoterodine, or a pharmaceutically acceptable salt thereof is to be administered three times per day.

21. The use of any one of claims 1-20, wherein the Compound 1 and fesoterodine are to be administered in separate pharmaceutical compositions.

22. The use of any one of claims 1-21, wherein the Compound 1 and fesoterodine are to be orally administered.

23. The use of any one of claims 1-22, wherein the fesoterodine, or a pharmaceutically acceptable salt thereof is to be administered in an extended release composition.

24. The use of any one of claims 1-23, wherein the patient is to be administered the Compound 1 at least one hour after the patient is to be administered the fesoterodine.


25. The use of claim 24, wherein the patient is to be administered the Compound 1 about four hours after the patient is to be administered the fesoterodine.

26. The use of any one of claims 1-25, wherein the administration provides a Compound 1 to desfesoterodine plasma concentration ratio of about 10:1 to about 1000:1.

27. The use of any one of claims 1-25, wherein the administration provides a Compound 1 to desfesoterodine plasma concentration ratio of about 100:1.

28. The use of any one of claims 1-23 or 26-27, wherein the Compound 1 and fesoterodine are to be administered in the same pharmaceutical composition.

29. The use of any one of claims 1-28, wherein the Compound 1 comprises the hydrochloride salt of formula:



.

30. The use of any one of claims 1-29, wherein the fesoterodine, or a pharmaceutically acceptable salt thereof comprises fesoterodine fumarate.

31. The use of any one of claims 1-30, wherein the dose and administration schedule of fesoterodine are selected to reduce the peripheral side effects of administering Compound 1 to the patient.